AgRP: The Peptide That Makes You Hungry by Blocking MC4R

Setmelanotide and MC4R

~10,000 neurons

A small population of AgRP neurons in the hypothalamic arcuate nucleus drives the hunger response by blocking melanocortin-4 receptors, overriding satiety signals from alpha-MSH.

Deem et al., The FEBS Journal, 2022

Deem et al., The FEBS Journal, 2022

View as image

Somewhere in the base of your brain, roughly 10,000 neurons hold the power to make you ravenously hungry. These neurons produce agouti-related peptide (AgRP), a neuropeptide that drives food intake by blocking melanocortin-4 receptors (MC4R) in downstream brain regions. When AgRP neurons fire, they override satiety signals and produce a sustained urge to eat that persists for hours. When they are silenced, appetite drops. This system is so fundamental that mutations in MC4R (the receptor AgRP blocks) are the most common monogenic cause of severe childhood obesity, as explored in setmelanotide: the MC4R agonist for rare genetic obesity syndromes.

The AgRP peptide sits at a critical junction in the brain's energy regulation circuit. It opposes alpha-melanocyte-stimulating hormone (alpha-MSH), the melanocortin peptide that activates MC4R to suppress appetite and increase energy expenditure. The balance between AgRP and alpha-MSH at MC4R determines, in part, whether you feel hungry or full. Sridhar et al. (2024) reviewed how MC4R mutations disrupt this balance, leading to early-onset obesity characterized by hyperphagia and reduced energy expenditure.^[1]

What Is AgRP?

Agouti-related peptide is a 132-amino-acid protein expressed almost exclusively in two locations: the arcuate nucleus of the hypothalamus and, as discovered more recently, the adrenal medulla. The biologically active fragment is the C-terminal domain (AgRP 83-132), a cystine-knot peptide that binds MC3R and MC4R with high affinity. The cystine-knot structure, formed by five disulfide bonds, gives AgRP unusual stability for a neuropeptide and structural similarity to certain toxins and growth factors.

AgRP is not simply a competitive antagonist at MC4R. It functions as an inverse agonist, meaning it suppresses the receptor's constitutive (baseline) signaling activity even in the absence of the agonist alpha-MSH. This distinction matters because MC4R has significant constitutive activity: it signals even when no ligand is bound. AgRP binding actively reduces this baseline signaling, producing an orexigenic (hunger-promoting) effect that goes beyond merely preventing alpha-MSH from activating the receptor. Ayers et al. (2018) described how this inverse agonism at MC4R contributes to the pathway dysfunction seen in obesity, and proposed stratifying patients by their specific MC4R signaling deficits to guide MC4R agonist therapy.^[2]

AgRP neurons co-express neuropeptide Y (NPY) and the inhibitory neurotransmitter GABA. All three signals promote feeding, but through different mechanisms and timescales. GABA provides rapid, acute feeding drive (onset within minutes). NPY provides intermediate-duration signaling. AgRP itself produces the slowest, longest-lasting feeding response, with effects persisting for up to 24 hours after a single activation event. This layered signaling architecture ensures that hunger, once initiated, sustains itself long enough to motivate food-seeking behavior.

How AgRP Drives Hunger Through MC4R

The melanocortin pathway operates as a push-pull system in the brain circuit that controls weight. Alpha-MSH, derived from the precursor peptide POMC, activates MC4R to suppress appetite and increase energy expenditure. AgRP does the opposite: it blocks MC4R to increase appetite and decrease energy expenditure. Both peptides are released from neurons in the arcuate nucleus, but from separate, functionally opposing populations.

MC4R-expressing neurons in the paraventricular nucleus of the hypothalamus (PVH) are the primary downstream targets. When alpha-MSH activates MC4R on these neurons, they initiate satiety signaling cascades. When AgRP blocks MC4R, those cascades are suppressed and feeding behavior increases. The net effect at any moment depends on the relative concentrations of AgRP and alpha-MSH at MC4R.

Choi et al. (2024) characterized the GIRK1 potassium channels expressed by both POMC and AgRP neurons in the arcuate nucleus, showing that these channels mediate inhibitory inputs and contribute to the reciprocal regulation of the two neuronal populations.^[3] When GIRK channels open in POMC neurons, alpha-MSH release decreases. When they open in AgRP neurons, AgRP release decreases. This shared ionic mechanism provides another layer of control over the melanocortin balance.

The clinical significance of this system is demonstrated by MC4R loss-of-function mutations, the most common monogenic cause of severe obesity. Sridhar et al. (2024) reviewed the genetics and found that MC4R mutations account for approximately 2-6% of severe early-onset obesity cases, with over 300 identified variants affecting receptor function.^[1] These patients are effectively locked into a state where the MC4R satiety signal is weakened, mimicking the effect of chronically elevated AgRP.

What Controls AgRP Neurons

AgRP neurons integrate metabolic signals from hormones, nutrients, and sensory cues to determine when and how strongly to promote feeding.

Fasting and ghrelin: Ghrelin, the stomach-derived "hunger hormone," is one of the most potent activators of AgRP neurons. Ghrelin levels rise before meals and fall after eating. When ghrelin binds its receptor (GHSR) on AgRP neurons, it triggers electrical activity and AgRP release. Fasting itself increases AgRP mRNA expression independently of ghrelin, through intracellular energy-sensing pathways.

Leptin and insulin: Both hormones inhibit AgRP neurons. Leptin, produced by fat tissue in proportion to fat mass, signals that energy stores are adequate and suppresses AgRP expression and neuronal firing. Insulin, released from the pancreas after meals, has a similar inhibitory effect. In leptin-resistant obesity, this inhibitory brake on AgRP fails, contributing to persistent hunger despite large fat stores.

Epigenetic regulation: Xie et al. (2022) discovered that the epigenetic enzyme TET3 controls AgRP neuron function and stress response behaviors by modifying DNA methylation patterns in these neurons.^[4] Loss of TET3 in AgRP neurons altered feeding behavior and stress responses, revealing that the hunger circuitry is not hardwired but epigenetically tunable. Environmental factors like diet, stress, and early-life nutrition can permanently modify how AgRP neurons respond to metabolic signals.

Fat sensing: Ge et al. (2025) showed that AgRP neurons express GPR40, a receptor for medium- and long-chain fatty acids, and that this receptor mediates dietary fat preference.^[5] When GPR40 was deleted specifically from AgRP neurons, mice lost their normal preference for high-fat food. This finding links fat detection directly to the hunger circuitry, suggesting AgRP neurons do not just drive general appetite but can bias food choice toward calorie-dense, fatty options.

AgRP Beyond the Hypothalamus

Outside the brain, AgRP has an unexpected second home. Gupta et al. (2017) demonstrated that AgRP is expressed in adrenal medullary chromaffin cells, the same cells that produce epinephrine and norepinephrine.^[6] These chromaffin cells also co-express NPY, mirroring the neurochemical profile of hypothalamic AgRP neurons.

Short-term fasting increased adrenal AgRP expression, paralleling the hypothalamic response. Gupta et al. tested whether adrenal AgRP has functional consequences by applying melanotan II (an MC3/4R agonist) to adrenal tissue. Melanotan II decreased synaptic transmission to chromaffin cells, and exogenous AgRP blocked this effect. The mechanism appears to be presynaptic: AgRP modulates the strength of sympathetic input to chromaffin cells by acting on MC3/4 receptors located on the preganglionic neurons that innervate the adrenal medulla. This means AgRP influences the sympathetic nervous system's activation of the adrenal gland during fasting, potentially adjusting the catecholamine response to match metabolic need.

This finding extends the role of AgRP beyond appetite regulation to autonomic nervous system modulation. The adrenal medulla's response to fasting involves not just the canonical hormonal signals (cortisol, epinephrine) but also a local melanocortin regulatory system using the same AgRP peptide that drives hunger in the brain.

Why GLP-1 Drugs Suppress Appetite: The AgRP Connection

McMorrow et al. (2025) provided a mechanistic explanation for why incretin receptor agonists like semaglutide and tirzepatide so powerfully suppress appetite.^[7] Using in vivo fiber photometry to monitor AgRP neuron activity in real time, they discovered that both GIP and GLP-1 receptor agonists inhibit AgRP neurons. The magnitude of neural inhibition was proportional to the food intake reduction produced by each drug.

A particularly relevant finding: dual GIP and GLP-1 receptor agonism (as in tirzepatide) inhibited AgRP neurons more potently than either agonist alone, and this greater inhibition corresponded to greater appetite suppression. This provides a cellular mechanism for tirzepatide's superior weight loss efficacy compared to GLP-1-only agonists in clinical trials.

McMorrow et al. also discovered distinct physiological and pharmacological roles for the two incretin hormones. Endogenous GIP (not GLP-1) was required for normal nutrient-mediated inhibition of AgRP neurons after meals. This suggests that the gut communicates satiety to the brain's hunger center primarily through GIP under normal conditions, while pharmacological doses of GLP-1 analogs achieve the same effect through a different but converging pathway. For how GLP-1 receptors in the brain's reward center contribute to appetite suppression beyond the melanocortin pathway, that article explores the reward-circuit dimension of GLP-1 drug action.

Sex, Aging, and AgRP Neuron Responses

Brothers et al. (2025) challenged the assumption that AgRP neuron biology, studied almost entirely in young male mice, applies universally.^[8] They examined AgRP/NPY neuron responses to different diets across both sexes and at different ages. Aging revealed divergent metabolic adaptations between males and females that were not apparent in young animals.

This matters because obesity risk, body fat distribution, and metabolic disease susceptibility all differ by sex and change with age. If AgRP neurons respond differently to dietary signals in older females versus older males, then appetite regulation strategies (pharmacological or dietary) that work in one population may not transfer directly to another. The finding underscores that preclinical research on appetite circuits, overwhelmingly conducted in young male rodents, may miss biologically important variation.

What Research Has Not Resolved

Despite progress, several questions about AgRP remain open. The precise mechanism by which AgRP produces feeding effects lasting up to 24 hours from a single activation event is not fully understood. The signaling duration far exceeds the expected lifetime of the peptide at its receptor, suggesting downstream transcriptional or synaptic remodeling mechanisms that have not been completely characterized.

Whether AgRP neurons are viable anti-obesity drug targets is debated. Early studies showed that acute ablation of AgRP neurons in adult mice caused starvation and death, suggesting they are indispensable for feeding behavior. However, gradual reduction of AgRP neuron activity does not produce the same effect, and recent research has argued that AgRP neurons may not be required for body weight regulation under ad libitum feeding conditions. This complicates the therapeutic calculus: blocking AgRP signaling might reduce appetite, but the system may compensate, or the intervention may carry unacceptable risks depending on how it is implemented.

The functional significance of adrenal AgRP in human physiology is unclear. Gupta et al. (2017) demonstrated it in mice, but whether human adrenal chromaffin cells express functionally relevant AgRP levels, and whether this changes in metabolic disease states, has not been established. The relationship between the KPV peptide derived from alpha-MSH and the AgRP/alpha-MSH balance also remains unexplored in the context of appetite regulation.

The Bottom Line

AgRP is a neuropeptide produced by arcuate nucleus neurons that drives hunger by acting as an inverse agonist at MC4R, suppressing both alpha-MSH-stimulated and constitutive receptor activity. Regulated by ghrelin, leptin, insulin, and epigenetic mechanisms, AgRP neurons integrate metabolic signals and sustain feeding drive for hours after activation. Recent research shows GLP-1 and GIP agonists suppress appetite partly by inhibiting AgRP neurons, while adrenal chromaffin cells express AgRP as part of the fasting response. Sex and age differences in AgRP neuron responses highlight gaps in current understanding.

Frequently Asked Questions

What is AgRP and what does it do?

Agouti-related peptide (AgRP) is a neuropeptide produced by neurons in the hypothalamic arcuate nucleus that drives hunger. It works by blocking melanocortin-4 receptors (MC4R) in the brain, suppressing satiety signals and increasing the motivation to eat. AgRP acts as an inverse agonist, meaning it reduces MC4R baseline activity even when no other signal is present. It is activated by fasting and ghrelin, and inhibited by leptin and insulin.

How does AgRP differ from alpha-MSH?

AgRP and alpha-MSH are opposing signals at the same receptor, MC4R. Alpha-MSH activates MC4R to suppress appetite and increase energy expenditure. AgRP blocks MC4R to increase appetite and decrease energy expenditure. Both are produced in the hypothalamic arcuate nucleus but by separate neuronal populations. The balance between these two peptides at MC4R determines whether the brain sends a "hungry" or "full" signal.

Does AgRP explain why GLP-1 drugs reduce appetite?

Partly. McMorrow et al. (2025) showed that both GLP-1 and GIP receptor agonists inhibit AgRP neurons, and the degree of inhibition correlates with appetite suppression. Dual GIP/GLP-1 agonism (as in tirzepatide) inhibits AgRP neurons more than either alone, which may explain tirzepatide's greater weight loss. AgRP neuron inhibition is one mechanism among several by which incretin drugs reduce appetite.

Is AgRP found outside the brain?

Yes. Gupta et al. (2017) showed that AgRP is expressed in adrenal medullary chromaffin cells in mice, where its expression increases during fasting. Adrenal AgRP modulates the strength of sympathetic nerve input to chromaffin cells via presynaptic MC3/4 receptors. This suggests AgRP plays a role in the sympathetic response to fasting beyond its hypothalamic appetite function.

Why are MC4R mutations linked to obesity?

MC4R is the receptor that alpha-MSH activates to suppress appetite. Loss-of-function mutations in MC4R are the most common single-gene cause of severe obesity, accounting for 2-6% of severe early-onset cases according to Sridhar et al. (2024). These mutations effectively lock the brain into a state where the satiety signal through MC4R is weakened, producing chronic overeating and reduced energy expenditure similar to the effect of elevated AgRP.

Do AgRP neurons respond differently in men and women?

In mice, yes. Brothers et al. (2025) found that AgRP/NPY neuron responses to diet diverge by sex and age. These differences were not apparent in young animals but emerged with aging. Since most appetite research uses young male rodents, these findings suggest that appetite regulation strategies may need to account for sex and age differences in AgRP neuron biology.